This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Melanoma

Receptor tyrosine kinase-like orphan receptor 1 (ROR1); ROR2

In vitro and mouse studies suggest inhibiting ROR2 could help treat invasive melanoma. Proliferative, ROR1+, noninvasive melanoma cells can phenotypically switch to a ROR2+, invasive phenotype. In noninvasive melanoma cells, small interfering RNA targeting ROR1 increased ROR2 levels and invasion compared with control siRNA. In mice with BRAF-mutant melanoma cells with low sensitivity to the BRAF inhibitor Zelboraf vemurafenib, siRNA targeting ROR2 sensitized cancer cells to vemurafenib. Next steps include developing a ROR2 inhibitor.
Daiichi Sankyo Co. Ltd., Chugai Pharmaceutical Co. Ltd. and Roche market Zelboraf to treat melanoma.

SciBX 6(45); doi:10.1038/scibx.2013.1288
Published online Nov. 21, 2013

Unpatented; unlicensed

O'Connell, M.P. et al. Cancer Discov.; published online Oct. 8, 2013;
doi:10.1158/2159-8290.CD-13-0005
Contact: Ashani T. Weeraratna,
The Wistar Institute, Philadelphia, Pa.
e-mail:
aweeraratna@wistar.org